Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.
A series of highly potent HIV protease inhibitors have been designed and synthesized. These compounds are active against various clinical viral isolates as well as wild-type virus. The synthesis and biological activity of these HIV protease inhibitors are discussed.
Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA. zhijian_lu@merck.com
Zhijian
Z
Lu
Subharekha
S
Raghavan
Joann
J
Bohn
Mark
M
Charest
Mark W
MW
Stahlhut
Carrie A
CA
Rutkowski
Amy L
AL
Simcoe
David B
DB
Olsen
William A
WA
Schleif
Anthony
A
Carella
Lori
L
Gabryelski
Lixia
L
Jin
Jiunn H
JH
Lin
Emilio
E
Emini
Kevin
K
Chapman
James R
JR
Tata
D000588:Amines; D019380:Anti-HIV Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D002460:Cell Line; D015195:Drug Design; D017320:HIV Protease Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology; D006571:Heterocyclic Compounds; D006801:Humans; D020128:Inhibitory Concentration 50; D009154:Mutation; D009842:Oligopeptides / Q000138:chemical synthesis / Q000494:pharmacology; D013329:Structure-Activity Relationship; D014779:Virus Replication / Q000187:drug effects
D000588:Amines; D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D006571:Heterocyclic Compounds; D009842:Oligopeptides